Supplementary Table1 from Long-term Therapy Outcomes of CD19/22 CAR T Cell Alone or with Autologous Stem Cell Transplantation for Relapsed/Refractory DLBCL

Xiaoying Zhang; Jue Wang; Na Wang; Yang Yang; Jinhuan Xu; Xiaojian Zhu; Gaoxiang Wang; Di Wang; Fankai Meng; Yi Xiao; Miao Zheng; Li Meng; Chunrui Li; Jia Wei; Yang Cao; Yicheng Zhang

doi:10.1158/2643-3230.31047040

Supplementary Table1 from Long-term Therapy Outcomes of CD19/22 CAR T Cell Alone or with Autologous Stem Cell Transplantation for Relapsed/Refractory DLBCL

2026 Open access

Read full text

Authors: Xiaoying Zhang, Jue Wang, Na Wang, Yang Yang, Jinhuan Xu, Xiaojian Zhu, Gaoxiang Wang, Di Wang, Fankai Meng, Yi Xiao, Miao Zheng, Li Meng

+4 more

Chunrui Li, Jia Wei, Yang Cao, Yicheng Zhang

DOI: 10.1158/2643-3230.31047040

Cited by: 0

Abstract

Adverse events occurred in all patients after the first month of Treatment.

Fields of Study & Subjects

CAR-T cell therapy research Lymphoma Diagnosis and Treatment T-cell and B-cell Immunology

Publication details

Publication date: 12 January 2026